Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.59 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.59 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15177332 | 0.96 | RAB9A (0.73) | RAB9ACYP3A4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL2560736 | 0.85 | HDAC6 (0.69) | RAB9ACYP3A4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL13680649 | 0.84 | HSD17B1 (0.63) | CYP3A4CYP2A6CYP2C9CYP2C19KDM4E | |
| SCHEMBL27623980 | 0.83 | RAB9A (0.71) | RAB9AMEN1POLBKMT2ANPC1 | |
| SCHEMBL1761545 | 0.83 | RAB9A (0.92) | RAB9AMEN1POLBKMT2ANPC1 | |
| SCHEMBL2254356 | 0.83 | HDAC6 (0.64) | RAB9ACYP3A4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL1356959 | 0.83 | LMNA (0.70) | RAB9ACYP3A4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL9910293 | 0.82 | HSD17B1 (0.61) | RAB9ACYP3A4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL3305569 | 0.82 | ESR1 (0.59) | CYP3A4CYP2A6CYP2C9CYP2C19KDM4E | |
| SCHEMBL10275320 | 0.82 | RAB9A (0.69) | RAB9AMEN1POLBKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478500-B | Coumarin two-photon initiator and synthesis method and application thereof | 浙江大学 | 2024-03-29 | — | — | CN | claimed |
| CN-114478500-B | Coumarin two-photon initiator and synthesis method and application thereof | 浙江大学 | 2024-03-29 | — | — | CN | disclosed |
| US-20230096028-A1 | BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2023-03-30 | — | — | US | disclosed |
| CN-114478500-A | Coumarin two-photon initiator and synthesis method and application thereof | 浙江大学 | 2022-05-13 | — | — | CN | disclosed |
| EP-3930845-A1 | BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-07-03 | — | — | US | disclosed |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-07-03 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-29 | — | — | US | disclosed |
| EP-1695972-A1 | PROCESS FOR PRODUCING 2-ACYLTHIOPHENE COMPOUND | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006063154-A1 | COMPOSITION FOR PROTEASOME INHIBITION | PROTEOLIX, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| EP-0588785-A1 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-03-30 | — | — | EP | disclosed |
| US-5185363-A | Administering for treatment of inflammatory diseases | ABBOTT LABORATORIES (US) | 1993-02-09 | — | — | US | disclosed |
| EP-0588785-A4 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS. | ABBOTT LAB (US) | 1991-12-30 | — | — | EP | disclosed |
| WO-1990012008-A1 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1990-10-18 | — | — | WO | disclosed |
| US-4105663-A | HYPOTENSIVE, BLOCKING AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-08-08 | — | — | US | disclosed |
| US-4093628-A | HYPOTENSIVE AGENTS, BLOCKING AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
| US-4082772-A | HYPOTENSIVE AGENTS, B-ADRENERGIC BLOCKING AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-04-04 | — | — | US | disclosed |
| US-4024156-A | Thiophene ethanolamines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | AR, SHBG, BRCA1 | RAB9A 4667/4885CYP3A4 1211/4885CYP2A6 412/4885 |
| US-20230096028-A1 | BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF | SOST, SOS1, IQGAP1 | RAB9A 163/4885CYP3A4 3876/4885CYP2A6 1564/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | RAB9A 2463/4885CYP3A4 1107/4885CYP2A6 1494/4885 |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | AR, FSHR, ESRRB | RAB9A 4089/4885CYP3A4 1950/4885CYP2A6 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.